153 related articles for article (PubMed ID: 23422111)
41. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
Kasenda B; Rehberg M; Thürmann P; Franzem M; Veelken H; Fritsch K; Schorb E; Finke J; Lebiedz D; Illerhaus G
Ann Hematol; 2012 Aug; 91(8):1257-64. PubMed ID: 22456893
[TBL] [Abstract][Full Text] [Related]
42. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome.
Tzankov A; Gschwendtner A; Augustin F; Fiegl M; Obermann EC; Dirnhofer S; Went P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2125-32. PubMed ID: 16609025
[TBL] [Abstract][Full Text] [Related]
43. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic Utility of the Germinal Center-associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms.
Menter T; Gasser A; Juskevicius D; Dirnhofer S; Tzankov A
Appl Immunohistochem Mol Morphol; 2015 Aug; 23(7):491-8. PubMed ID: 25203428
[TBL] [Abstract][Full Text] [Related]
45. Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features.
Møller MB; Nielsen O; Pedersen NT
Am J Clin Pathol; 2001 Mar; 115(3):404-12. PubMed ID: 11242797
[TBL] [Abstract][Full Text] [Related]
46. Pretreatment Hemoglobin as an Independent Prognostic Factor in Primary Central Nervous System Lymphomas.
Le M; Garcilazo Y; Ibáñez-Juliá MJ; Younan N; Royer-Perron L; Benazra M; Mokhtari K; Houillier C; Hoang-Xuan K; Alentorn A
Oncologist; 2019 Sep; 24(9):e898-e904. PubMed ID: 30867243
[TBL] [Abstract][Full Text] [Related]
47. [A retrospective analysis of 8 cases with primary central nervous system lymphoma].
Zhou XQ; Liu XQ; Kong JC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Oct; 23(5):455-7. PubMed ID: 12905861
[TBL] [Abstract][Full Text] [Related]
48. [The clinical features and prognostic factors of 22 patients with primary central nervous system lymphoma].
Yu H; Xie Y; Wang G
Zhonghua Nei Ke Za Zhi; 2001 May; 40(5):325-8. PubMed ID: 11798596
[TBL] [Abstract][Full Text] [Related]
49. Central nervous system lymphoma: patterns of incidence in Indian population and effect of steroids on stereotactic biopsy yield.
Manoj N; Arivazhagan A; Mahadevan A; Bhat DI; Arvinda HR; Devi BI; Sampath S; Chandramouli BA
Neurol India; 2014; 62(1):19-25. PubMed ID: 24608449
[TBL] [Abstract][Full Text] [Related]
50. Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients.
Fudaba H; Momii Y; Hirakawa T; Onishi K; Asou D; Matsushita W; Kawasaki Y; Sugita K; Fujiki M
Sci Rep; 2021 Jan; 11(1):1206. PubMed ID: 33441719
[TBL] [Abstract][Full Text] [Related]
51. Primary central nervous system lymphoma.
Gelabert-González M; Castro Bouzas D; Serramito-García R; Frieiro Dantas C; Aran Echabe E
Neurologia; 2013 Jun; 28(5):283-93. PubMed ID: 22703636
[TBL] [Abstract][Full Text] [Related]
52. New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).
Gomes Candido Reis D; Levy D; Lage LAPC; Culler HF; Rocha V; Bydlowski SP; Nogueira Zerbini MC; Pereira J
Brain Behav; 2021 Apr; 11(4):e02061. PubMed ID: 33591648
[TBL] [Abstract][Full Text] [Related]
53. Expression of Tim-1 in primary CNS lymphoma.
Kishimoto W; Nishikori M; Arima H; Miyoshi H; Sasaki Y; Kitawaki T; Shirakawa K; Kato T; Imaizumi Y; Ishikawa T; Ohno H; Haga H; Ohshima K; Takaori-Kondo A
Cancer Med; 2016 Nov; 5(11):3235-3245. PubMed ID: 27709813
[TBL] [Abstract][Full Text] [Related]
54. Prognostic impact of LIM domain only 2 (LMO2) in chronic myelogenous leukaemia.
Atay MH; Ozatli D; Kelkitli E; Yildiz L; Turgut M; Guler N; Toptas T
Histopathology; 2013 Aug; 63(2):293-4. PubMed ID: 23879574
[No Abstract] [Full Text] [Related]
55. Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme.
Cerqua R; Balestrini S; Perozzi C; Cameriere V; Renzi S; Lagalla G; Mancini G; Montanari M; Leoni P; Scerrati M; Iacoangeli M; Silvestrini M; Luzzi S; Provinciali L
Neurol Sci; 2016 Jan; 37(1):23-29. PubMed ID: 26233232
[TBL] [Abstract][Full Text] [Related]
56. Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma.
Kaulen LD; Galluzzo D; Hui P; Barbiero F; Karschnia P; Huttner A; Fulbright R; Baehring JM
J Neurooncol; 2019 Aug; 144(1):107-115. PubMed ID: 31190317
[TBL] [Abstract][Full Text] [Related]
57. Primary central nervous system lymphoma involving the hypothalamic-pituitary axis: a case series and pooled analysis.
Shin DW; Kim JH; Kim YH; Cho YH; Hong SH
J Neurooncol; 2020 Apr; 147(2):339-349. PubMed ID: 32221784
[TBL] [Abstract][Full Text] [Related]
58. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling.
Alame M; Cornillot E; Cacheux V; Rigau V; Costes-Martineau V; Lacheretz-Szablewski V; Colinge J
Theranostics; 2021; 11(8):3565-3579. PubMed ID: 33664848
[No Abstract] [Full Text] [Related]
59. Angiogenesis in primary central nervous system lymphoma (PCNSL).
Takeuchi H; Matsuda K; Kitai R; Sato K; Kubota T
J Neurooncol; 2007 Sep; 84(2):141-5. PubMed ID: 17406788
[TBL] [Abstract][Full Text] [Related]
60. [Analysis of the Clinical Characteristics and Prognostic Factors of 31 Cases of Primary Central Nervous System Lymphoma].
Fu L; Chen L; Wei N; Huang DY; Shen J; Wang JS; Wang YN; Cui H; Yang LZ; Wang Z
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1061-5. PubMed ID: 27531775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
